Bimacure intrauteriinsuspensioon Eesti - eesti - Ravimiamet

bimacure intrauteriinsuspensioon

bimeda animal health limited - tsefapiriin - intrauteriinsuspensioon - 500mg 19g 19g 10tk

ORLISTAT POLPHARMA 60MG kõvakapsel Eesti - eesti - Ravimiamet

orlistat polpharma 60mg kõvakapsel

pharmaceutical works polpharma s.a. - orlistaat - kõvakapsel - 60mg 42tk; 60mg 60tk; 60mg 84tk

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Euroopa Liit - eesti - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

NILODUX gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

nilodux gastroresistentne kõvakapsel

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 40mg 28tk

NILODUX gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

nilodux gastroresistentne kõvakapsel

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 20mg 28tk

LINGABAT kõvakapsel Eesti - eesti - Ravimiamet

lingabat kõvakapsel

pharmaswiss ceska republika s.r.o. - pregabaliin - kõvakapsel - 75mg 14tk

LINGABAT kõvakapsel Eesti - eesti - Ravimiamet

lingabat kõvakapsel

pharmaswiss ceska republika s.r.o. - pregabaliin - kõvakapsel - 25mg 56tk

LINGABAT kõvakapsel Eesti - eesti - Ravimiamet

lingabat kõvakapsel

pharmaswiss ceska republika s.r.o. - pregabaliin - kõvakapsel - 150mg 14tk; 150mg 56tk

NILODUX gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

nilodux gastroresistentne kõvakapsel

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 30mg 28tk

NILODUX gastroresistentne kõvakapsel Eesti - eesti - Ravimiamet

nilodux gastroresistentne kõvakapsel

pharmaswiss ceska republika s.r.o. - duloksetiin - gastroresistentne kõvakapsel - 60mg 28tk